Table 3.

Patients with MI discharged in 2012: switch pattern for dual antiplatelet therapy during the first 365 days after MI

Drug treatment	Number of discharged patients	Number of patients switching	Median time (days) to switch	Number of patients switching to clopidogrel	Number of patients switching to ticagrelor	Number of patients switching to prasugrel
PCI-treated patients
Clopidogrel	719	25	73 (44–119)	0	18	7
Ticagrelor	2198	214	110 (62–209)	210	0	<5
Prasugrel	524	33	147 (90–230)	29	<5	0
Clopidogrel without ASA	74	<5	83 (12–90)	0	<5	<5
Ticagrelor without ASA	110	18	84 (57–210)	18	0	0
Prasugrel without ASA	29	<5	200 (149–310)	<5	0	0
No P2Y12 antagonist only ASA	118	29	49 (15–119)	13	7	9
No P2Y12 antagonist or ASA	24	14	34 (14–136)	8	<5	<5
Non-PCI-treated patients
Clopidogrel	635	14	148 (73–213)	0	13	<5
Ticagrelor	868	102	107 (49–208)	102	0	0
Prasugrel	25	<5	52 (52–52)	0	<5	0
Clopidogrel without ASA	161	<5	44 (33–106)	0	<5	0
Ticagrelor without ASA	68	11	133 (108–154)	10	0	<5
No P2Y12 antagonist only ASA	765	83	77 (13–167)	58	22	<5
No P2Y12 antagonist or ASA	424	21	92 (55–178)	16	5	0

ASA, acetyl salicylic acid; MI, myocardial infarction; PCI, percutaneous coronary intervention.